RNA Splicing
Targeted Cancer Therapies
Internal Receptors
Abnormal Proliferation
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Updated: May 13, 2025

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
Published on: November 19, 2019
Mitchell G Lawrence1, Shivakumar Keerthikumar2, Scott L Townley3
1Department of Anatomy and Developmental Biology, Biomedicine Discovery Institute, Monash University, Clayton, Australia; Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia; Cabrini Institute, Cabrini Health, Malvern, Australia; Melbourne Urological Research Alliance, Monash University, Clayton, Australia.
Androgen receptor (AR) variants like ARv567es drive prostate cancer therapy resistance by altering gene expression. Identifying ARv567es may help guide treatment decisions for resistant prostate cancer.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: